Alkermes (NASDAQ:ALKS) and Immuneering (NASDAQ:IMRX) Head-To-Head Comparison

Immuneering (NASDAQ:IMRX) and Alkermes (NASDAQ:ALKS) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, valuation, dividends, earnings, analyst recommendations, institutional ownership and risk.

Volatility & Risk

Immuneering has a beta of -0.36, indicating that its share price is 136% less volatile than the S&P 500. Comparatively, Alkermes has a beta of 0.49, indicating that its share price is 51% less volatile than the S&P 500.

Earnings & Valuation

This table compares Immuneering and Alkermes”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immuneering	$320,000.00	180.48	-$53.47 million	($1.97)	-0.94
Alkermes	$1.66 billion	3.04	$355.76 million	$1.95	16.02

Alkermes has higher revenue and earnings than Immuneering. Immuneering is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Immuneering and Alkermes’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Immuneering	N/A	-79.19%	-69.08%
Alkermes	22.15%	24.92%	14.55%

Analyst Recommendations

This is a breakdown of current recommendations for Immuneering and Alkermes, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immuneering	1	3	4	0	2.38
Alkermes	1	2	8	0	2.64

Immuneering currently has a consensus price target of $12.20, suggesting a potential upside of 555.91%. Alkermes has a consensus price target of $36.00, suggesting a potential upside of 15.27%. Given Immuneering’s higher probable upside, research analysts clearly believe Immuneering is more favorable than Alkermes.

Institutional & Insider Ownership

67.7% of Immuneering shares are held by institutional investors. Comparatively, 95.2% of Alkermes shares are held by institutional investors. 25.0% of Immuneering shares are held by company insiders. Comparatively, 4.9% of Alkermes shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Alkermes beats Immuneering on 10 of the 13 factors compared between the two stocks.

About Immuneering

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.

About Alkermes

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.